Solvay expands development pact with Wyeth

Solvay and Wyeth Pharmceutical are expanding their existing neuroscience co-development and co-commercialization agreement to include research in neuroscience. The neuroscience co-development and co-commercialization partnership announced in April 2004 between Solvay and Wyeth resulted in an NDA for bifeprunox for the treatment of patients with schizophrenia. Meanwhile development continues on two other early-phase neuroscience projects, SLV313 and SLV314, which were part of that agreement.

- check out the release on the deal

Related Articles:
Solvay earns $25M as obesity drug advances. Report
Wyeth licenses Pharmacopeia's JAK3 program. Report